Fluicell AB (publ) (FLUI.ST)
SEK 0.04
(0.5%)
SEK 0.04
(0.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -26.87 Million SEK | -29.66% |
| 2022 | -21.72 Million SEK | -0.15% |
| 2021 | -21.69 Million SEK | -27.42% |
| 2020 | -17.02 Million SEK | 8.87% |
| 2019 | -18.68 Million SEK | -26.42% |
| 2018 | -14.77 Million SEK | -98.74% |
| 2017 | -7.43 Million SEK | -49.74% |
| 2016 | -4.96 Million SEK | -29.02% |
| 2015 | -3.84 Million SEK | -135.16% |
| 2014 | -1.63 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -8.01 Million SEK | 5.08% |
| 2024 Q2 | -5.58 Million SEK | 36.03% |
| 2023 Q3 | -6.05 Million SEK | 17.31% |
| 2023 Q4 | -8.44 Million SEK | -39.48% |
| 2023 Q2 | -7.32 Million SEK | -35.5% |
| 2023 FY | -28.17 Million SEK | -29.66% |
| 2023 Q1 | -5.4 Million SEK | 21.09% |
| 2022 Q4 | -6.85 Million SEK | -144.29% |
| 2022 FY | -21.72 Million SEK | -0.15% |
| 2022 Q3 | -2.8 Million SEK | 60.84% |
| 2022 Q2 | -7.16 Million SEK | -45.79% |
| 2022 Q1 | -4.91 Million SEK | 14.34% |
| 2021 Q3 | -4.71 Million SEK | 20.22% |
| 2021 Q4 | -5.73 Million SEK | -21.64% |
| 2021 FY | -21.69 Million SEK | -27.42% |
| 2021 Q1 | -5.33 Million SEK | -11.51% |
| 2021 Q2 | -5.9 Million SEK | -10.72% |
| 2020 Q3 | -5.24 Million SEK | -61.17% |
| 2020 Q4 | -4.78 Million SEK | 8.72% |
| 2020 Q1 | -3.74 Million SEK | 33.59% |
| 2020 FY | -17.02 Million SEK | 8.87% |
| 2020 Q2 | -3.25 Million SEK | 13.11% |
| 2019 Q3 | -4.31 Million SEK | 5.76% |
| 2019 Q4 | -5.63 Million SEK | -30.63% |
| 2019 FY | -18.68 Million SEK | -26.42% |
| 2019 Q1 | -4.15 Million SEK | 12.69% |
| 2019 Q2 | -4.58 Million SEK | -10.36% |
| 2018 Q1 | -2.52 Million SEK | -18.4% |
| 2018 Q4 | -4.75 Million SEK | -35.61% |
| 2018 Q3 | -3.5 Million SEK | 12.31% |
| 2018 Q2 | -3.99 Million SEK | -58.49% |
| 2018 FY | -14.77 Million SEK | -98.74% |
| 2017 Q4 | -2.13 Million SEK | -1.62% |
| 2017 FY | -7.43 Million SEK | -49.74% |
| 2017 Q1 | -1.26 Million SEK | -25.15% |
| 2017 Q2 | -1.94 Million SEK | -53.96% |
| 2017 Q3 | -2.09 Million SEK | -7.71% |
| 2016 Q4 | -1.01 Million SEK | 0.0% |
| 2016 FY | -4.96 Million SEK | -29.02% |
| 2015 FY | -3.84 Million SEK | -135.16% |
| 2014 FY | -1.63 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 89.204% |
| Ziccum AB (publ) | -21.56 Million SEK | -24.671% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -63.886% |
| BioArctic AB (publ) | 252.64 Million SEK | 110.639% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -3080.947% |
| Mendus AB (publ) | -100.65 Million SEK | 73.295% |
| Genovis AB (publ.) | 54.22 Million SEK | 149.57% |
| Intervacc AB (publ) | -93.57 Million SEK | 71.277% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -73.279% |
| Active Biotech AB (publ) | -46.48 Million SEK | 42.176% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 249.253% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 51.497% |
| Aptahem AB (publ) | -10.1 Million SEK | -166.003% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 91.64% |
| Kancera AB (publ) | -65.04 Million SEK | 58.674% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 80.033% |
| Saniona AB (publ) | -81.06 Million SEK | 66.843% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -117.274% |
| Biovica International AB (publ) | -126.07 Million SEK | 78.68% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 36.763% |
| AcouSort AB (publ) | -17.48 Million SEK | -53.708% |
| Xintela AB (publ) | -57.23 Million SEK | 53.04% |
| Abliva AB (publ) | -96.54 Million SEK | 72.16% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 91.724% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -666.876% |
| OncoZenge AB (publ) | -15.9 Million SEK | -69.029% |
| Amniotics AB (publ) | -29.07 Million SEK | 7.547% |
| 2cureX AB (publ) | -36.36 Million SEK | 26.081% |
| CombiGene AB (publ) | -36.3 Million SEK | 25.964% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -83.6% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 93.007% |
| Camurus AB (publ) | 532.35 Million SEK | 105.049% |
| Corline Biomedical AB | -1.78 Million SEK | -1403.3% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 85.13% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 35.516% |
| I-Tech AB | 24.43 Million SEK | 210.002% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 96.591% |
| Cyxone AB (publ) | -21.66 Million SEK | -24.089% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 74.634% |
| Biosergen AB | -27.26 Million SEK | 1.416% |
| Cantargia AB (publ) | -290.01 Million SEK | 90.732% |
| NextCell Pharma AB | -43.17 Million SEK | 37.74% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 85.13% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -57.221% |
| Nanologica AB (publ) | -69.96 Million SEK | 61.581% |
| SynAct Pharma AB | -224.49 Million SEK | 88.027% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 39.155% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -12.21% |
| LIDDS AB (publ) | -40.67 Million SEK | 33.916% |
| Lipum AB (publ) | -37.25 Million SEK | 27.849% |
| BioInvent International AB (publ) | -369.94 Million SEK | 92.734% |
| Alzinova AB (publ) | -16.52 Million SEK | -62.686% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 89.395% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -320.428% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 76.642% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -33.467% |
| Simris Alg AB (publ) | -36.63 Million SEK | 26.63% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 81.661% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 91.341% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 75.766% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -132.397% |